For instance, HER2-targeted medicines like lapatinib and neratinib resistance in breast cancer patients has been linked to alterations in the kinase domain of the HER2 receptor (Rexer and Arteaga, 2012). The gene discussed is ERBB2; the disease is breast cancer.